NeoGenomics Inc (NEO)vsNovartis AG ADR (NVS)
NEO
NeoGenomics Inc
$10.90
-3.63%
HEALTHCARE · Cap: $1.37B
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 7484% more annual revenue ($56.58B vs $745.97M). NVS leads profitability with a 23.9% profit margin vs -13.3%. NEO appears more attractively valued with a PEG of 2.09. NEO earns a higher WallStSmart Score of 51/100 (C-).
NEO
Buy51
out of 100
Grade: C-
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.8%
Fair Value
$51.46
Current Price
$10.90
$40.56 discount
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 130.6% YoY
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Expensive relative to growth rate
Smaller company, higher risk/reward
Weak financial health signals
ROE of -12.0% — below average capital efficiency
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : NEO
The strongest argument for NEO centers on EPS Growth, Price/Book. Revenue growth of 11.1% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : NEO
The primary concerns for NEO are PEG Ratio, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
NEO profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
NEO carries more volatility with a beta of 1.80 — expect wider price swings.
NEO is growing revenue faster at 11.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NEO scores higher overall (51/100 vs 49/100) and 11.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NeoGenomics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?